نتائج البحث

Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.

• Authors : Yang T; Hanx Biopharmaceuticals, Ltd., Wuhan, Hubei, PRC, China.; Ke H

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/drug therapy

• Source: Scientific reports [Sci Rep] 2024 Apr 19; Vol. 14 (1), pp. 9032. Date of Electronic Publication: 2024 Apr 19.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.

• Authors : Du M; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Rd., Hangzhou, 310003, Zhejiang Province, People's Republic of China.; Institute of Hematology, Zhejiang University, Hangzhou, China.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic* ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/metabolism

• Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Mar 13; Vol. 43 (1), pp. 79. Date of Electronic Publication: 2024 Mar 13.Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966

تفاصيل العنوان

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens.

• Authors : Milnerowicz S; Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.; Maszewska J

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/drug therapy

• Source: International journal of molecular sciences [Int J Mol Sci] 2023 Oct 31; Vol. 24 (21). Date of Electronic Publication: 2023 Oct 31.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

Clinical Aspects and Significance of β-Chemokines, γ-Chemokines, and δ-Chemokines in Molecular Cancer Processes in Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasms (MDS).

• Authors : Korbecki, Jan^1,2 (AUTHOR) ; Bosiacki, Mateusz² (AUTHOR); Stasiak, Piotr¹ (AUTHOR)

• Source: Cancers. Oct2024, Vol. 16 Issue 19, p3246. 29p.

تفاصيل العنوان

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.

• Authors : Heitmann JS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.

Subjects: Antineoplastic Agents* ; Drug-Related Side Effects and Adverse Reactions* ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/drug therapy

• Source: Journal of hematology & oncology [J Hematol Oncol] 2023 Aug 17; Vol. 16 (1), pp. 96. Date of Electronic Publication: 2023 Aug 17.Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722

تفاصيل العنوان

Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier.

• Authors : Wu X; Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/drug therapy; Animals

• Source: Journal of nanobiotechnology [J Nanobiotechnology] 2023 Apr 11; Vol. 21 (1), pp. 126. Date of Electronic Publication: 2023 Apr 11.Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155

تفاصيل العنوان

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.

• Authors : Fooks K; Lady Davis Institute for Medical Research, Montreal, Canada.; Department of Medicine, McGill University, Montreal, Canada.

Subjects: Cytarabine*/Cytarabine*/Cytarabine*/pharmacology ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/drug therapy ; Eukaryotic Initiation Factor-4A*/Eukaryotic Initiation Factor-4A*/Eukaryotic Initiation Factor-4A*/antagonists & inhibitors

• Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2022 Dec 09; Vol. 41 (1), pp. 340. Date of Electronic Publication: 2022 Dec 09.Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966

تفاصيل العنوان

Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review.

• Authors : Hao Q; The Center of Gerontology and Geriatrics (National Clinical Research Center for Geriatrics), West China Hospital, Sichuan University, Chengdu, China.; School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada.

Subjects: Leukemia, Myeloid, Acute* ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use; Humans

• Source: PloS one [PLoS One] 2022 Dec 05; Vol. 17 (12), pp. e0278578. Date of Electronic Publication: 2022 Dec 05 (Print Publication: 2022).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.

• Authors : Hoang DH; Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA 91010, USA.; Buettner R

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Arsenicals*/Arsenicals*/Arsenicals*/pharmacology

• Source: International journal of molecular sciences [Int J Mol Sci] 2022 Jun 12; Vol. 23 (12). Date of Electronic Publication: 2022 Jun 12.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.

• Authors : Cortes JE; Georgia Cancer Center, Augusta University, 1410 Laney Walker Rd., CN2116, Augusta, GA, 30912, USA. .; Lin TL

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Cytarabine/Cytarabine/Cytarabine/*therapeutic use ; Daunorubicin/Daunorubicin/Daunorubicin/*therapeutic use

• Source: Journal of hematology & oncology [J Hematol Oncol] 2021 Jul 13; Vol. 14 (1), pp. 110. Date of Electronic Publication: 2021 Jul 13.Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722

تفاصيل العنوان